Lineage Cell Therapeutics, Inc. LCTX
Set alert
1.01 USD 0.00 0.00%
As of Nov 3, 11:22 AM ET
1.01 Day range 1.04
0.88 52-week range 1.99
- YTD
- -39.52%
- 1 year
- -48.47%
- Open
- 1.02
- Prev close
- 1.01
- Mkt cap
- 255.44M
- Vol
- 169.85K
- Avg vol
- 1.27M
- EPS
- -0.19
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 1.01
- High
- 1.04
- Forward P/E
- -3.66
- Beta
- 1.28
- Short ratio
- 35.21
- Inst. own
- 50.56%
- Dividend
- 0.00
- Ex-div date
- 50-d avg
- 0.7364
- 200-d avg
- 0.96025
- 1y target
- 4.83
1M chart
Signals (11)
| Name | Date | Ago |
|---|---|---|
| SMA: Bullish | Nov 3, 2026 | 1 hour ago |
| SMA: Bearish | Oct 30, 2026 | 4 days ago |
| SMA: Bullish | Oct 27, 2026 | 1 week ago |
| SMA: Bullish | Oct 22, 2026 | 1 week ago |
| SMA: Bearish | Oct 21, 2026 | 1 week ago |
| SMA: Bullish | Oct 20, 2026 | 2 weeks ago |
| SMA: Bearish | Oct 19, 2026 | 2 weeks ago |
| SMA: Bullish | Oct 15, 2026 | 2 weeks ago |
| SMA: Bearish | Oct 12, 2026 | 3 weeks ago |
| SMA: Bullish | Oct 8, 2026 | 3 weeks ago |
| MACD: Buy Signal | Oct 8, 2026 | 3 weeks ago |
Analyst view
Price target (mean) 4.83 +378.5% upside
Now 1.01
- Target (low)
- 2.00
- Target (mean)
- 4.83
- Target (high)
- 9.00
Ratings (0m) 7 6 buy · 1 hold · 0 sell
- Strong buy2
- Buy4
- Hold1
- Sell0
- Strong sell0
Recommendation trend
- This month 7
- 1 month ago 7
- 2 months ago 7
Earnings and revenue estimates
Consensus for the coming quarters and fiscal years
| Period | EPS estimate | Low – high | Year ago | EPS growth | Revenue estimate | Revenue growth | Analysts |
|---|---|---|---|---|---|---|---|
| Current quarter | -0.0325 | -0.04 – -0.02 | -0.0272 | -19.5% | 1.62M | -23.5% | 4 |
| Next quarter | -0.04 | -0.04 – -0.04 | -0.04 | 0.0% | 1.36M | -5.8% | 2 |
| Current year | -0.11 | -0.12 – -0.10 | -0.1235 | +10.9% | 8.25M | -7.7% | 3 |
| Next year | -0.09333 | -0.13 – -0.06 | -0.11 | +15.2% | 9.99M | +21.0% | 3 |
Upgrades and downgrades
The latest rating changes
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Dec 4, 2024 | HC Wainwright & Co. | Maintained | Buy | Buy |
| Nov 20, 2024 | D. Boral Capital | Maintained | Buy | Buy |
| Nov 18, 2024 | D. Boral Capital | Initiated | — | Buy |
| Aug 20, 2024 | Craig-Hallum | Initiated | — | Buy |
| May 6, 2024 | HC Wainwright & Co. | Reiterated | Buy | Buy |
| Mar 8, 2024 | HC Wainwright & Co. | Reiterated | Buy | Buy |
| Feb 13, 2024 | HC Wainwright & Co. | Reiterated | Buy | Buy |
| Feb 5, 2024 | Cantor Fitzgerald | Reiterated | Overweight | Overweight |
| Aug 11, 2023 | HC Wainwright & Co. | Reiterated | Buy | Buy |
| Jul 25, 2023 | Cantor Fitzgerald | Reiterated | Overweight | Overweight |
| Jul 24, 2023 | HC Wainwright & Co. | Reiterated | Buy | Buy |
| May 12, 2023 | HC Wainwright & Co. | Reiterated | Buy | Buy |
| Apr 26, 2023 | HC Wainwright & Co. | Reiterated | — | Buy |
| Mar 10, 2023 | HC Wainwright & Co. | Reiterated | — | Buy |
| Nov 2, 2022 | Baird | Initiated | — | Outperform |
| Jun 14, 2022 | B. Riley Securities | Initiated | — | Buy |
| Aug 19, 2021 | Noble Capital Markets | Initiated | — | Outperform |
| Mar 31, 2021 | Cantor Fitzgerald | Initiated | — | Overweight |
| Sep 17, 2020 | Noble Capital Markets | Initiated | — | Outperform |